Phase 2 N=46 Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=123 GRASPA Treatment for Patients With Acute Myeloblastic Leukemia
Acute Myeloid Leukemia
Primary: Overall Survival — 4.8; 6.4 months
Phase 4 N=8 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Melanoma
Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change
Phase 2 N=30 Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Efficacy Primary Endpoint - Percentage of Patients Responding to Treatment — 0; 11; 10 Participants
N/A N=10 Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Hematologic Diseases · Hematologic Malignancies
Primary: Numbers of Participants With Disease-free Survival. — 10 participants
Phase 2 N=49 Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
Metastatic Cancer · Sarcoma
Primary: Status of FAS Ligand in Pre-chemotherapy Sample — 7; 5; 1; 1 participants
Phase 2 N=26 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Diseases
Primary: Clinical Response (Complete and Partial) — 0; 4; 4; 5 Participants
Phase 2 N=60 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Phase 2 N=84 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Biphenotypic Leukemia · Acute Myeloid Leukemia · de Novo Myelodysplastic Syndrome
Primary: Phase 1: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Mitoxantrone — 18 mg/m^2
Phase 3 N=85 GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, in Relapse
Primary: Duration of Asparaginase Activity >100 U/L During Induction — 18.9; 8.5 days
Phase 2 N=47 Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Stem Cell Transplantation · Leukemia
Primary: Number of Participants With Grade 4 Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) Plerixafor — 1; 4; 7; 4 participants
Phase 2 N=130 Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
Leukemia
Primary: Overall Response Rate — 23; 31; 23 Participants
Phase 3 N=114 Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
Neutropenia · Infection
Primary: Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response — 42.9; 41.7 percentage of participants — p=0.73
Phase 1 N=48 CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Granulocytic Sarcoma · Recurrent Adult Acute Myeloid Leukemia
Primary: Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as…
Phase 2 N=60 FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Participant Overall Response Rate (ORR) at 6 Months Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions. — 100 Percentage of Participants
N/A N=13 High-Risk Neuroblastoma Chemotherapy Without G-CSF
Neuroblastoma
Primary: Incidence of Infection — 6 infections
Phase 2 N=57 Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Phase 3 N=27 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
Childhood Acute Lymphoblastic Leukemia in Remission · Childhood Acute Myeloid Leukemia in Remission · Childhood Chronic Myelogenous Leukemia
Primary: Estimated Two-year Event-free Survival (EFS) — 66; 83 Percentage of patients
Phase 2 N=13 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
Sarcoma
Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin
N/A N=14 Stereotactic Radiation Therapy for Pediatric Sarcomas
Sarcoma · Metastatic Disease · Bony Sites
Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Phase 2 N=15 Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Juvenile Myelomonocytic Leukemia
Primary: Determine Probability of Long-term Disease Free Survival in JMML — 67 Percentage of participants
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Phase 2 N=66 Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1) — NA; NA Participants
Phase 2 N=17 External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma
Soft Tissue Sarcoma
Primary: Overall Response Rate (ORR) — 9; 3; 6 participants
Phase 1 N=9 Detection of Graft Versus Host Disease With [18F]F-AraG
Graft Versus Host Disease
Primary: Distribution of Acute GVHD Grades (MAGIC Criteria) at Time of PET/CT Scan — 0; 2; 0; 0 Participants
Phase 3 N=13 Collection of Bone Marrow From Donors Treated With or Without Filgrastim
Healthy Stem Cell Donor · No Evidence of Disease
Primary: Percentage of Participants With Short-term Adverse Events in G-CSF (Filgrastim) Stimulated Bone Marrow (G-BM) Donors — 0 Percentage of patients
Phase 2 N=12 PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Multiple Myeloma · Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Proportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions — 0.50000; 0.9167; 0.9167…
Phase 2 N=10 Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases
Synovial Sarcoma · Single or Multiple Lung Metastases
Primary: Number of Participants Evaluated for Toxicity — 10 Participants
Phase 2 N=72 Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
Graft Versus Host Disease · Systemic Scleroderma
Primary: Significant Clinical Response — 9; 10 participants